A recent study indicates that people who stop using new slimming jabs like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who stop traditional lifestyle programs.
Published data in a leading medical journal demonstrates that while overweight people often shed substantial amounts of their body weight while undergoing treatment, the mass is regained at an estimated rate of 0.8 kg per month after stopping.
"People using these drugs need to be cognizant of the potential of rapid weight regain when the therapy ends," stated expert Dr. Susan Jebb.
Such speed of regain implies a reversion to original weight within about a year and a half.
Weighing Treatments
The research, which examined 37 of studies involving thousands of patients, contrasted the results of the injectable medications with other pills.
Scientists emphasize that people who shed pounds through diet and exercise typically see a less rapid weight regain—perhaps 100 grams monthly—after stopping.
Understanding the Quick Regain
Doctors propose the way of the drugs accounts for the accelerated weight return.
These medications imitate a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Artificially providing GLP-1 concentrations far above than normal might result in the system to generate a reduced amount of its own natural GLP-1, and could lessen sensitivity to its actions," explained Dr. Adam Collins, a dietetics expert.
"Discontinuation of this medication means hunger is no longer kept in check, making binge eating far more likely."
An Ongoing Disease?
Health authorities suggest the jabs for individuals with obesity-related health risks, accompanied by recommended diet and exercise modifications.
Professionals say that, considering the significant potential of weight regain, the treatment should be considered ongoing.
This perspective is supported by drug manufacturers, who note that the findings "underscore the long-term character of obesity," similar to managing conditions like hypertension.
Patient Testimonies
People who have come off the medication explain a powerful return of hunger.
"It was like a trigger that goes on and I was suddenly extremely hungry," described a patient.
This difficulty is exacerbated if patients have not developed sustainable lifestyle or habit modifications during treatment.
Widespread Adoption
Recent estimates suggest that millions of adults in the UK have tried these injections in the last 12 months, with demand being substantial.
- Use is greater among women compared to men.
- The 40s and 50s age group shows the greatest level of interest.
- Many access the medications through private healthcare rather than the NHS.
Finally, clinicians emphasize that while GLP-1 drugs are powerful tools for shedding pounds, they are not a standalone cure and long-term success hinges on combined lifestyle changes.
